Developer docs
API playgroundTry for free, no card

Search company profiles

Cleveland HeartLab

Full company profile

uuid0008mt2

Namestring
Cleveland HeartLab
Legal namestring
Cleveland HeartLab, Inc.
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Cleveland HeartLab, Inc. is a specialty clinical laboratory headquartered in Cleveland, Ohio, focused exclusively on cardiometabolic disease testing. Founded in 2000 by Stanley Hazen and Jake Orville, the company operates as the Quest® Cardiometabolic Center of Excellence™ at Cleveland HeartLab® under the corporate umbrella of Quest Diagnostics Incorporated (NYSE: DGX), a wholly-owned subsidiary structure that provides national laboratory infrastructure, billing systems, and provider network reach.

The company's core offering is a proprietary multimarker test menu spanning inflammation biomarkers (F2-Isoprostanes, hsCRP, Oxidized LDL, Lp-PLA2 Activity, Myeloperoxidase, Microalbumin, ADMA/SDMA), advanced lipid testing (HDL Function Panel with HDLfx pCAD Score, NMR LipoFraction, Apolipoprotein B/A1, Small-Dense LDL, Lipoprotein(a)), metabolic markers (TMAO, Adiponectin), vitamin and supplement testing (OmegaCheck™, CoQ10, Vitamin D), genetic assays (ApoE genotyping, CYP2C19 polymorphism), and additional cardiovascular markers (AspirinWorks®, Galectin-3, High Sensitivity Troponin T). These assays are performed at the company's Cleveland laboratory using proprietary chemistry methods and are supported by clinical education, peer consultation services, and an extensive clinical references library.

Commercially, Cleveland HeartLab operates a B2B sales-led model targeting healthcare providers — physicians, cardiologists, primary care practices, and clinical groups — who order tests on behalf of patients. Specimens are collected at provider offices or Quest Diagnostics Patient Service Centers and shipped to Cleveland for analysis. Tests are billed through standard insurance, Medicare, or Medicaid reimbursement channels. Distribution occurs through direct sales relationships, the Cleveland HeartLab web portal, and integration with Quest Diagnostics' Quanum Lab Services Manager. The company holds CLIA certification and HIPAA compliance, and prior to its acquisition by Quest Diagnostics had raised approximately $48M in venture funding between 2010 and 2016.

Short descriptiontext

Cleveland HeartLab is a specialty clinical laboratory that provides proprietary cardiometabolic and inflammation biomarker testing to healthcare providers. Operating as a Quest Diagnostics subsidiary, it serves physicians, cardiologists, and primary care practices ordering advanced cardiovascular risk assessment tests.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCleveland, United States
HQ citystring
Cleveland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiometabolic diagnostics, inflammation biomarker testing, cardiovascular risk assessment, advanced lipid testing, specialty clinical laboratory
Industry2 codes
1Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
CodeHLAGAEABPrimaryYes
2Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
CodeHLAAAMACPrimaryNo
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Specialty Clinical Laboratory / Cardiometabolic Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Laboratory Testing Services
TypeProfessional Services
Description

Cleveland HeartLab provides specialized cardiometabolic laboratory testing services to healthcare providers. Tests are ordered by physicians and billed through standard laboratory billing processes, likely insurance or government healthcare programs. The company offers a comprehensive test menu covering inflammation, lipids, metabolic, and genetic markers.

clevelandheartlab.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Quest® Cardiometabolic Center of Excellence™
Description

A national cardiometabolic center of excellence focused on identifying hidden heart disease risk through advanced diagnostic testing.

clevelandheartlab.com
Core offering1 text field

Cleveland HeartLab is a specialty clinical laboratory that performs cardiometabolic diagnostic testing ordered by healthcare providers, covering inflammation biomarkers, advanced lipid panels, metabolic markers, genetic tests, and cardiovascular assays. Samples are collected at provider offices or Quest Diagnostics Patient Service Centers, shipped to the Cleveland laboratory, and results are returned via a secure web portal. The company also supplies specimen collection materials and offers clinical education and consultation services to support provider adoption and patient management.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 50% of patients who have a heart attack or stroke have normal cholesterol levels
+1 more record
Product overview1 text field

Cleveland HeartLab operates as the Quest® Cardiometabolic Center of Excellence™ at Cleveland HeartLab®, providing specialized laboratory testing services focused on identifying clinically silent risk factors for cardiometabolic diseases. The company's testing portfolio includes inflammation testing (F2-Isoprostanes, hsCRP, Oxidized LDL, Lp-PLA2 Activity, Myeloperoxidase, Microalbumin, ADMA/SDMA), advanced lipid testing (HDL Function Panel with HDLfx, LipoFraction NMR, Apolipoprotein testing, Small-Dense LDL, Lipoprotein(a)), metabolic testing (TMAO, Adiponectin), vitamin and supplement testing (OmegaCheck™, CoQ10, Vitamin D), genetic testing (Apolipoprotein E, CYP2C19), and other cardiovascular tests (AspirinWorks®, Galectin-3, High Sensitivity Troponin T). The company offers a web portal for providers to access patient test results and provides clinical consultation services.

Product and service8 records
1Inflammation Testing Panel
CategoryDiagnostic laboratory testing
Description

Comprehensive inflammation biomarker testing panel measuring F2-Isoprostanes (oxidative stress), hsCRP (general inflammation), Oxidized LDL, Lp-PLA2 Activity (vascular inflammation), Myeloperoxidase (MPO), ADMA/SDMA, and Microalbumin for cardiovascular risk assessment, ordered by healthcare providers.

2Advanced Lipid Testing
CategoryDiagnostic laboratory testing
Description

Advanced lipid testing services including HDL Function Panel with HDLfx pCAD Score, NMR LipoFraction analysis, Apolipoprotein B and A1 testing, Small-Dense LDL measurement, and Lipoprotein(a) analysis for cardiovascular risk stratification, offered to healthcare providers.

3Metabolic Testing
CategoryDiagnostic laboratory testing
Description

Metabolic testing services including TMAO (gut microbiome metabolite), Adiponectin, OmegaCheck™ (omega-3/omega-6 fatty acid profile), Coenzyme Q10 (CoQ10), and Vitamin D (25 OH) for comprehensive cardiometabolic risk evaluation, ordered by healthcare providers.

4Genetic Cardiovascular Testing
CategoryGenetic diagnostic testing
Description

Genetic testing services including Apolipoprotein E (ApoE) genotyping for lipid regulation polymorphisms and CYP2C19 polymorphism testing to support personalized cardiovascular drug metabolism decisions (e.g., clopidogrel), offered to healthcare providers.

5AspirinWorks®
CategoryDiagnostic laboratory testing
Description

ELISA test measuring 11-dehydrothromboxane B2 levels to detect aspirin effect in apparently healthy individuals, ordered by healthcare providers to assess aspirin therapy effectiveness.

6Galectin-3
CategoryDiagnostic laboratory testing
Description

Laboratory test measuring Galectin-3, a marker of cardiac fibrosis and adverse cardiac remodeling, complementary to natriuretic peptides, ordered by healthcare providers for cardiovascular risk assessment.

7High-Sensitivity Troponin T
CategoryDiagnostic laboratory testing
Description

High-sensitivity cardiac troponin T test for diagnosis of myocardial infarction and prediction of cardiovascular mortality, ordered by healthcare providers for acute and chronic cardiac risk evaluation.

8Clinical Education and Consultation Services
CategoryClinical support services
Description

Clinical education and consultation services providing peer-to-peer engagement with PhDs, clinical lipid specialists, and clinical educators who support healthcare providers in test interpretation, risk factor identification, and patient management considerations across the cardiometabolic continuum of care.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthers
Description

Cleveland HeartLab operates as a subsidiary of Quest Diagnostics, branded as the Quest® Cardiometabolic Center of Excellence™ at Cleveland HeartLab®. This integration provides national laboratory infrastructure, billing systems, provider network access, and operational support. Quest Diagnostics is a leading provider of diagnostic information services with significant market presence in the United States.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston Heart Diagnostics is a specialty clinical laboratory offering advanced cardiovascular and metabolic disease testing, including advanced lipid panels, inflammation markers, and cardiometabolic risk assessment—directly comparable to Cleveland HeartLab's core focus area.

TypeDirect peer
Description

HDL was a specialty clinical laboratory focused on cardiometabolic disease testing using advanced biomarkers and was acquired by Quest Diagnostics in 2015, making it a direct functional peer and now a sibling asset within the same parent.

TypeDirect peer
Description

True Health Diagnostics is a specialty laboratory offering advanced cardiovascular, metabolic, and inflammation-related testing panels to healthcare providers—a closely comparable commercial specialty lab in the cardiometabolic testing niche.

TypeDirect peer
Description

Genova Diagnostics is a specialty clinical laboratory offering advanced cardiovascular inflammation and metabolic testing panels to healthcare providers, comparable to Cleveland HeartLab's specialty biomarker focus.

TypeBroad incumbent
Description

LabCorp is one of the two largest U.S. clinical laboratory networks and offers an extensive menu of routine and specialty testing including cardiovascular and inflammation panels—overlapping with Cleveland HeartLab but as part of a much broader routine testing portfolio.

TypeDirect peer
Description

ARUP Laboratories is a national specialty reference laboratory affiliated with the University of Utah, offering an extensive esoteric test menu including cardiovascular and inflammatory biomarkers—comparable as a specialized clinical reference lab serving hospital systems.

TypeDirect peer
Description

Mayo Clinic Laboratories is an academic specialty reference laboratory offering a broad esoteric test menu including advanced cardiovascular and inflammation biomarkers—comparable as a specialty lab with deep clinical expertise serving complex testing needs.

TypeEmerging player
Description

Singulex is a specialty biomarker company developing high-sensitivity immunoassays for cardiac and inflammatory disease detection—an emerging player with technology focused on similar cardiovascular biomarker measurement challenges addressed by Cleveland HeartLab's panels.

TypeEmerging player
Description

SpectraCell Laboratories is a specialty clinical laboratory offering advanced cardiovascular and metabolic testing including inflammation and lipid-related markers—an emerging specialty player with a comparable boutique clinical lab model.

TypeBroad incumbent
Description

Quest Diagnostics is the parent company of Cleveland HeartLab and the largest U.S. clinical laboratory network, offering a broad portfolio including cardiovascular risk testing—relevant both as parent and as the broader incumbent whose routine testing portfolio encompasses the specialty niche.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cleveland HeartLab

Specialty Clinical Laboratory / Cardiometabolic Diagnosticsclevelandheartlab.com

Cleveland HeartLab is a specialty clinical laboratory that provides proprietary cardiometabolic and inflammation biomarker testing to healthcare providers. Operating as a Quest Diagnostics subsidiary, it serves physicians, cardiologists, and primary care practices ordering advanced cardiovascular risk assessment tests.

What Cleveland HeartLab does

Cleveland HeartLab, Inc. is a specialty clinical laboratory headquartered in Cleveland, Ohio, focused exclusively on cardiometabolic disease testing. Founded in 2000 by Stanley Hazen and Jake Orville, the company operates as the Quest® Cardiometabolic Center of Excellence™ at Cleveland HeartLab® under the corporate umbrella of Quest Diagnostics Incorporated (NYSE: DGX), a wholly-owned subsidiary structure that provides national laboratory infrastructure, billing systems, and provider network reach.

The company's core offering is a proprietary multimarker test menu spanning inflammation biomarkers (F2-Isoprostanes, hsCRP, Oxidized LDL, Lp-PLA2 Activity, Myeloperoxidase, Microalbumin, ADMA/SDMA), advanced lipid testing (HDL Function Panel with HDLfx pCAD Score, NMR LipoFraction, Apolipoprotein B/A1, Small-Dense LDL, Lipoprotein(a)), metabolic markers (TMAO, Adiponectin), vitamin and supplement testing (OmegaCheck™, CoQ10, Vitamin D), genetic assays (ApoE genotyping, CYP2C19 polymorphism), and additional cardiovascular markers (AspirinWorks®, Galectin-3, High Sensitivity Troponin T). These assays are performed at the company's Cleveland laboratory using proprietary chemistry methods and are supported by clinical education, peer consultation services, and an extensive clinical references library.

Commercially, Cleveland HeartLab operates a B2B sales-led model targeting healthcare providers — physicians, cardiologists, primary care practices, and clinical groups — who order tests on behalf of patients. Specimens are collected at provider offices or Quest Diagnostics Patient Service Centers and shipped to Cleveland for analysis. Tests are billed through standard insurance, Medicare, or Medicaid reimbursement channels. Distribution occurs through direct sales relationships, the Cleveland HeartLab web portal, and integration with Quest Diagnostics' Quanum Lab Services Manager. The company holds CLIA certification and HIPAA compliance, and prior to its acquisition by Quest Diagnostics had raised approximately $48M in venture funding between 2010 and 2016.

Cleveland HeartLab firmographics

Firmographics
Name
Cleveland HeartLab
Legal name
Cleveland HeartLab, Inc.
Website
http://www.clevelandheartlab.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
51–100 employees
Short description
Cleveland HeartLab is a specialty clinical laboratory that provides proprietary cardiometabolic and inflammation biomarker testing to healthcare providers. Operating as a Quest Diagnostics subsidiary, it serves physicians, cardiologists, and primary care practices ordering advanced cardiovascular risk assessment tests.
Ownership category
akta.pro rank

Cleveland HeartLab industry classification

Industry
Product category
Specialty Clinical Laboratory / Cardiometabolic Diagnostics
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro primary industry
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
akta.pro secondary industry
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

  • Cardiometabolic diagnostics
  • Inflammation biomarker testing
  • Cardiovascular risk assessment
  • Advanced lipid testing
  • Specialty clinical laboratory

Where Cleveland HeartLab is headquartered

Location

Headquarters

HQ city
Cleveland
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cleveland HeartLab business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Laboratory Testing Services: Cleveland HeartLab provides specialized cardiometabolic laboratory testing services to healthcare providers. Tests are ordered by physicians and billed through standard laboratory billing processes, likely insurance or government healthcare programs. The company offers a comprehensive test menu covering inflammation, lipids, metabolic, and genetic markers.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Cleveland HeartLab product offering

Product offering

Core offering

Cleveland HeartLab is a specialty clinical laboratory that performs cardiometabolic diagnostic testing ordered by healthcare providers, covering inflammation biomarkers, advanced lipid panels, metabolic markers, genetic tests, and cardiovascular assays. Samples are collected at provider offices or Quest Diagnostics Patient Service Centers, shipped to the Cleveland laboratory, and results are returned via a secure web portal. The company also supplies specimen collection materials and offers clinical education and consultation services to support provider adoption and patient management.

Product overview

Cleveland HeartLab operates as the Quest® Cardiometabolic Center of Excellence™ at Cleveland HeartLab®, providing specialized laboratory testing services focused on identifying clinically silent risk factors for cardiometabolic diseases. The company's testing portfolio includes inflammation testing (F2-Isoprostanes, hsCRP, Oxidized LDL, Lp-PLA2 Activity, Myeloperoxidase, Microalbumin, ADMA/SDMA), advanced lipid testing (HDL Function Panel with HDLfx, LipoFraction NMR, Apolipoprotein testing, Small-Dense LDL, Lipoprotein(a)), metabolic testing (TMAO, Adiponectin), vitamin and supplement testing (OmegaCheck™, CoQ10, Vitamin D), genetic testing (Apolipoprotein E, CYP2C19), and other cardiovascular tests (AspirinWorks®, Galectin-3, High Sensitivity Troponin T). The company offers a web portal for providers to access patient test results and provides clinical consultation services.

Differentiator

Problem solved

Functional benefit

Brands

  • Quest® Cardiometabolic Center of Excellence™: A national cardiometabolic center of excellence focused on identifying hidden heart disease risk through advanced diagnostic testing.

Products and services

  • Inflammation Testing Panel Comprehensive inflammation biomarker testing panel measuring F2-Isoprostanes (oxidative stress), hsCRP (general inflammation), Oxidized LDL, Lp-PLA2 Activity (vascular inflammation), Myeloperoxidase (MPO), ADMA/SDMA, and Microalbumin for cardiovascular risk assessment, ordered by healthcare providers.
  • Advanced Lipid Testing Advanced lipid testing services including HDL Function Panel with HDLfx pCAD Score, NMR LipoFraction analysis, Apolipoprotein B and A1 testing, Small-Dense LDL measurement, and Lipoprotein(a) analysis for cardiovascular risk stratification, offered to healthcare providers.
  • Metabolic Testing Metabolic testing services including TMAO (gut microbiome metabolite), Adiponectin, OmegaCheck™ (omega-3/omega-6 fatty acid profile), Coenzyme Q10 (CoQ10), and Vitamin D (25 OH) for comprehensive cardiometabolic risk evaluation, ordered by healthcare providers.
  • Genetic Cardiovascular Testing Genetic testing services including Apolipoprotein E (ApoE) genotyping for lipid regulation polymorphisms and CYP2C19 polymorphism testing to support personalized cardiovascular drug metabolism decisions (e.g., clopidogrel), offered to healthcare providers.
  • AspirinWorks® ELISA test measuring 11-dehydrothromboxane B2 levels to detect aspirin effect in apparently healthy individuals, ordered by healthcare providers to assess aspirin therapy effectiveness.
  • Galectin-3 Laboratory test measuring Galectin-3, a marker of cardiac fibrosis and adverse cardiac remodeling, complementary to natriuretic peptides, ordered by healthcare providers for cardiovascular risk assessment.
  • High-Sensitivity Troponin T High-sensitivity cardiac troponin T test for diagnosis of myocardial infarction and prediction of cardiovascular mortality, ordered by healthcare providers for acute and chronic cardiac risk evaluation.
  • Clinical Education and Consultation Services Clinical education and consultation services providing peer-to-peer engagement with PhDs, clinical lipid specialists, and clinical educators who support healthcare providers in test interpretation, risk factor identification, and patient management considerations across the cardiometabolic continuum of care.

Quantifiable outcome

  • 50% of patients who have a heart attack or stroke have normal cholesterol levels
  • +1 more outcomes

Companies that use Cleveland HeartLab

Customer profile

Segments2 records

Ideal customer profiles1 record

Cleveland HeartLab technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Cleveland HeartLab partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Quest DiagnosticscoreOthersCleveland HeartLab operates as a subsidiary of Quest Diagnostics, branded as the Quest® Cardiometabolic Center of Excellence™ at Cleveland HeartLab®. This integration provides national laboratory infrastructure, billing systems, provider network access, and operational support. Quest Diagnostics is a leading provider of diagnostic information services with significant market presence in the United States.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Cleveland HeartLab competitors and assessment

Company assessment

Direct peers

  • Boston Heart Diagnostics: Boston Heart Diagnostics is a specialty clinical laboratory offering advanced cardiovascular and metabolic disease testing, including advanced lipid panels, inflammation markers, and cardiometabolic risk assessment—directly comparable to Cleveland HeartLab's core focus area.
  • Health Diagnostics Laboratory (HDL): HDL was a specialty clinical laboratory focused on cardiometabolic disease testing using advanced biomarkers and was acquired by Quest Diagnostics in 2015, making it a direct functional peer and now a sibling asset within the same parent.
  • True Health Diagnostics: True Health Diagnostics is a specialty laboratory offering advanced cardiovascular, metabolic, and inflammation-related testing panels to healthcare providers—a closely comparable commercial specialty lab in the cardiometabolic testing niche.
  • Genova Diagnostics: Genova Diagnostics is a specialty clinical laboratory offering advanced cardiovascular inflammation and metabolic testing panels to healthcare providers, comparable to Cleveland HeartLab's specialty biomarker focus.
  • ARUP Laboratories: ARUP Laboratories is a national specialty reference laboratory affiliated with the University of Utah, offering an extensive esoteric test menu including cardiovascular and inflammatory biomarkers—comparable as a specialized clinical reference lab serving hospital systems.
  • Mayo Clinic Laboratories: Mayo Clinic Laboratories is an academic specialty reference laboratory offering a broad esoteric test menu including advanced cardiovascular and inflammation biomarkers—comparable as a specialty lab with deep clinical expertise serving complex testing needs.

Broad incumbents

  • LabCorp (Laboratory Corporation of America): LabCorp is one of the two largest U.S. clinical laboratory networks and offers an extensive menu of routine and specialty testing including cardiovascular and inflammation panels—overlapping with Cleveland HeartLab but as part of a much broader routine testing portfolio.
  • Quest Diagnostics Incorporated: Quest Diagnostics is the parent company of Cleveland HeartLab and the largest U.S. clinical laboratory network, offering a broad portfolio including cardiovascular risk testing—relevant both as parent and as the broader incumbent whose routine testing portfolio encompasses the specialty niche.

Emerging players

  • Singulex: Singulex is a specialty biomarker company developing high-sensitivity immunoassays for cardiac and inflammatory disease detection—an emerging player with technology focused on similar cardiovascular biomarker measurement challenges addressed by Cleveland HeartLab's panels.
  • SpectraCell Laboratories: SpectraCell Laboratories is a specialty clinical laboratory offering advanced cardiovascular and metabolic testing including inflammation and lipid-related markers—an emerging specialty player with a comparable boutique clinical lab model.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Cleveland HeartLab social profiles

Digital presence

Cleveland HeartLab compliance and trust

Trust signal

Compliance2 records

Cleveland HeartLab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cleveland HeartLab leadership team

Management profile

Number of profiles

Profiles6 records

Cleveland HeartLab funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cleveland HeartLab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cleveland HeartLab

What does Cleveland HeartLab do?

Cleveland HeartLab is a specialty clinical laboratory that performs cardiometabolic diagnostic testing ordered by healthcare providers, covering inflammation biomarkers, advanced lipid panels, metabolic markers, genetic tests, and cardiovascular assays. Samples are collected at provider offices or Quest Diagnostics Patient Service Centers, shipped to the Cleveland laboratory, and results are returned via a secure web portal. The company also supplies specimen collection materials and offers clinical education and consultation services to support provider adoption and patient management.

Is Cleveland HeartLab a public or private company?

Cleveland HeartLab is a private company. It is classified as corporate owned and is currently operating.

When was Cleveland HeartLab founded?

Cleveland HeartLab was founded in 2000. It employs 51 to 100 people.

Where is Cleveland HeartLab based?

Cleveland HeartLab is headquartered in Cleveland, United States, in the North America region.

How does Cleveland HeartLab make money?

One revenue line is on record: laboratory Testing Services.

Who are Cleveland HeartLab's main competitors?

Direct peers on record are Boston Heart Diagnostics, Health Diagnostics Laboratory (HDL), True Health Diagnostics, Genova Diagnostics, ARUP Laboratories and Mayo Clinic Laboratories. Broad incumbents are LabCorp (Laboratory Corporation of America) and Quest Diagnostics Incorporated. Emerging players are Singulex and SpectraCell Laboratories.

Does Cleveland HeartLab have an API?

No public API is recorded for Cleveland HeartLab.

What industry is Cleveland HeartLab in?

Cleveland HeartLab's product category is Specialty Clinical Laboratory / Cardiometabolic Diagnostics. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireInflammation Testing Prompts Care Changes Leading to Significantly Lower Levels in Patients with Increased Cardiovascular Risk Due to Diabetes or Pre-DiabetesResearchers from MDVIP and Cleveland HeartLab published a retrospective study in the Journal of International Medical Research analyzing approximately 285,000 patients over five years, finding that those whose physicians ordered myeloperoxidase (MPO) inflammation testing achieved substantial reductions in MPO levels—68.5 percent among diabetes patients, 73.7 percent among pre-diabetes patients, and 72.2 percent among non-diabetic patients. The investigators attributed these declines to heightened cardiovascular risk awareness prompted by test results, leading to subsequent behavioral changes or medication adjustments. The study supports growing evidence that monitoring inflammatory status can help lower cardiovascular risk, particularly for the nearly half of heart attack patients who have normal cholesterol levels.PR NewswireQuest Diagnostics Completes Acquisition of Cleveland HeartLab and Formalizes R&D Collaboration with Cleveland ClinicQuest Diagnostics announced the completion of its acquisition of Cleveland HeartLab, establishing a national center of excellence for heart disease diagnostics at Cleveland HeartLab's existing facility in Cleveland. The acquisition combines Cleveland HeartLab's inflammation-based cardiovascular risk evaluation with Quest's Cardio IQ lipid particle analysis and genetic testing capabilities. In connection with the deal, Quest Diagnostics and Cleveland Clinic formalized a strategic collaboration to accelerate commercialization of emerging innovations from Cleveland Clinic's Lerner Research Institute.PR NewswireQuest Diagnostics to Acquire Cleveland HeartLab and Form Strategic Collaboration with Cleveland ClinicQuest Diagnostics announced a definitive agreement to acquire Cleveland HeartLab, a cardiovascular disease diagnostic services company, from equity investors including Cleveland Clinic, with the transaction expected to close in Q4 2017 subject to regulatory approval. Quest and Cleveland Clinic are simultaneously forming a strategic collaboration to evaluate biomarkers discovered by Cleveland Clinic's Lerner Research Institute, with Quest retaining rights to independently develop test services from these innovations. The acquisition aims to establish a national center of excellence in diagnostic information services at Cleveland HeartLab's laboratory in Cleveland, Ohio, combining Cleveland HeartLab's inflammation-based risk assessment with Quest's Cardio IQ lipid particle analysis capabilities.PR NewswireCleveland HeartLab Adds Two Additional Patents to its Extensive Intellectual Property Position for the Myeloperoxidase (MPO) test, a key predictor of Major Cardiac EventsCleveland HeartLab Inc. announced the issuance of two new U.S. patents (No. 9,581,597 and No. 9,612,242) for Myeloperoxidase (MPO) testing, expanding its intellectual property portfolio to 26 issued patents and 15 pending applications. The company holds exclusive licensing rights to MPO testing technology, which was originally discovered and developed at the Cleveland Clinic and is recognized in over 100 peer-reviewed publications as a key measure of vascular inflammation linked to cardiovascular disease. A recent study published in the Journal of Medical Economics found that combining MPO testing with standard lipid testing could reduce heart attacks and strokes by approximately 10% compared to cholesterol testing alone.PR NewswireCleveland HeartLab Adds New Patent to its Extensive Intellectual Property Position for the Myeloperoxidase (MPO) Test, a Powerful Biomarker for Inflammation and its Role in Major Cardiac EventsCleveland HeartLab Inc. announced receiving U.S. Patent No. 9,575,065 for Myeloperoxidase (MPO) testing, a biomarker for vascular inflammation and cardiovascular disease risk, originally developed at the Cleveland Clinic. The company now holds 24 issued patents and 17 pending applications for its MPO testing technology. According to a publication in the Journal of Medical Economics, combining MPO testing with standard lipid testing could reduce heart attacks and strokes by approximately 10% compared to cholesterol testing alone.PR NewswireCleveland HeartLab Launches Only Clinical Test for Measuring TMAO, an important measure of Gut Dysfunction Associated with Cardiovascular Disease RiskCleveland HeartLab Inc. announced the launch of a new clinical blood test for measuring TMAO (trimethylamine-N-oxide), a gut-derived metabolite strongly associated with cardiovascular disease risk, which was developed and validated by the company and licensed from Cleveland Clinic. The TMAO test, discovered by Cleveland Clinic researchers and recognized by the American Heart Association as a Top 10 advance in heart disease science in 2013, measures levels of a compound linked to heart attack, stroke, and death risk in otherwise healthy patients. Procter & Gamble is separately working on an over-the-counter product to help consumers manage their TMAO levels.FinSMEsCleveland HeartLab Raises $3MCleveland HeartLab completed a $3 million financing round with local business leaders and Glengary LLC, Second Generation Ltd., and Zapis Capital Group. The funds will expand reference laboratory operations, increase marketing, and advance marker pipelines like dysfunctional HDL and nitrotyrosine toward profitability.